Adam J. Gadzinski, MD, MS, on the Research Coming Out of SUO This Year
Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).
In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting clinical instructor in the Department of Urology at the University of Washington, discussed what is most exciting about the research being presented this year at the 21st Annual Meeting of the Society of Urologic Oncology (SUO).
Transcription:
I think a lot of the discussions have been around some of the new systemic treatments in prostate cancer and the genomic mutations in prostate cancer and how those are just now starting to guide our therapies for advanced prostate cancer. That's a very exciting place.
In the last 10 years, there's been numerous advances in men with metastatic prostate cancer. For decades, it was hormone suppression, whether that was achieved with shots or removing the testicles, and that was it. And now we're kind of an embarrassment of riches, and we keep getting more and now we're finding which specific ones work best for which specific patients with a subtype of cancer. So now we can accurately say we're getting to the personalized medicine that we've been talking a lot about for the last 20 years. We're finally getting there now.
FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer
